Moleculin Biotech Inc (NASDAQ:MBRX)’s traded shares stood at 6.35 million during the last session, with the company’s beta value hitting 1.95. At the close of trading, the stock’s price was $1.27, to imply an increase of 0.79% or $0.01 in intraday trading. The MBRX share’s 52-week high remains $10.35, putting it -714.96% down since that peak but still an impressive 68.5% since price per share fell to its 52-week low of $0.40.

Moleculin Biotech Inc (NASDAQ:MBRX) trade information

After registering a 0.79% upside in the last session, Moleculin Biotech Inc (MBRX) has traded red over the past five days. The 5-day price performance for the stock is -9.29%, and -23.49% over 30 days. With these gigs, the year-to-date price performance is -25.29%.

An assessment of the company’s 5-year growth patterns shows that annual earnings grew an estimated 18.25% for the past 5-year period. While 2025 is set for a 49.80% return in earnings, projections for the next 5 years are at 36.38% annually.

MBRX Dividends

Moleculin Biotech Inc has its next earnings report out in March. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.

We also have Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund as the top two Mutual Funds with the largest holdings of the Moleculin Biotech Inc (MBRX) shares. Going by data provided on Sep 30, 2024 , Vanguard Total Stock Market Index Fund holds roughly 42.47 shares. This is just over 1.02% of the total shares, with a market valuation of $53934.0. Data from the same date shows that the other fund manager holds a little less at 30.31, or 0.73% of the shares, all valued at about 38498.0.